Miglustat for treatment of Niemann-Pick C disease: a randomised
Por um escritor misterioso
Descrição
PDF] Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study
Pharmaceutical Benefits Scheme (PBS) Miglustat, capsule, 100 mg, Zavesca® - November 2011
Niemann-Pick type C disease – the tip of the iceberg? A review of neuropsychiatric presentation, diagnosis and treatment, BJPsych Bulletin
Different Niemann-Pick C1 Genotypes Generate Protein Phenotypes that Vary in their Intracellular Processing, Trafficking and Localization
Chronic Cyclodextrin Treatment of Murine Niemann-Pick C Disease Ameliorates Neuronal Cholesterol and Glycosphingolipid Storage and Disease Progression
Oxidative Stress: A Pathogenic Mechanism for Niemann-Pick Type C Disease
Dermatologic Manifestations of Niemann-Pick Disease: Background, Pathophysiology, Etiology
Niemann-Pick Disease, Type C1 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study - The Lancet Neurology
Frontiers Adult-Onset Niemann–Pick Disease Type C: Rapid Treatment Initiation Advised but Early Diagnosis Remains Difficult
Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatment - Mengel - 2021 - Journal of Inherited
Effects of Miglustat on Stabilization of Neurological Disorder in Niemann–Pick Disease Type C: Iranian Pediatric Case Series - Parvaneh Karimzadeh, Seyed Hassan Tonekaboni, Mahmoud Reza Ashrafi, Yousef Shafeghati, Alireza Rezayi, Shadab Salehpour
Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study, Orphanet Journal of Rare Diseases
Cost-effectiveness of miglustat versus symptomatic therapy of Niemann–Pick disease type C
de
por adulto (o preço varia de acordo com o tamanho do grupo)
